Calithera Biosciences Announces CB-839 Clinical Data Selected for Oral Presentation at the 28th EORTC-NCI-AACR Symposium on M...
September 07 2016 - 8:00AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage
biotechnology company focused on the discovering and developing
novel small molecule drugs directed against tumor metabolism and
tumor immunology targets for the treatment of cancer, today
announced that clinical data for its lead drug candidate CB-839,
the company's novel, orally bioavailable glutaminase inhibitor,
will be presented at the 28th Annual EORTC-NCI-AACR Symposium on
Molecular Targets and Cancer Therapeutics, which is being held from
November 29 to December 2, 2016 in Munich, Germany. Clinical
results to be presented in a plenary session will be focused on
data from Calithera’s CB-839 Phase I combination trial with
everolimus in renal cell carcinoma.
Phase 1 Study of CB-839, a small molecule inhibitor of
glutaminase, in combination with everolimus in patients with clear
cell and papillary renal cell carcinoma
Presenter: Funda Meric-Bernstam, M.D. Anderson Cancer Center
Plenary Session 2, Proffered Paper Session, Room 14
Wednesday, November 30, 2016, 4:30 p.m. CET
Two additional posters will be presented with preclinical
results from CB-839 and the company’s novel metabolic immune
checkpoint inhibitor CB-1158, respectively.
CB-839, a selective glutaminase inhibitor, has
anti-tumor activity in renal cell carcinoma and synergizes with
everolimus and receptor tyrosine kinase inhibitors
Presenter: Ethan Emberley, Calithera Biosciences
Poster Session: Molecular Targeted Agents II, Board P055
Thursday, December 1, 2016, 10:15 a.m.-5:00 p.m. CET
Arginase inhibitor CB-1158 elicits immune-mediated
anti-tumor responses as a single agent and enhances the efficacy of
other immunotherapies
Presenter: Suzanne Steggerda, Calithera Biosciences
Poster Session: Immunotherapy, Board P121
Wednesday, November 30, 2016, 10:15 a.m.-5:00 CET
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical
company focused on discovering and developing novel small molecule
drugs directed against tumor metabolism and tumor immunology
targets for the treatment of cancer. Calithera’s lead product
candidate, CB-839, is a potent, selective, reversible and orally
bioavailable inhibitor of glutaminase. CB-839 takes advantage of
the pronounced dependency many cancers have on the nutrient
glutamine for growth and survival. It is currently being evaluated
in Phase 1/2 clinical trials in combination with standard of care
agents. CB-1158 is a first-in-class immuno-oncology metabolic
checkpoint inhibitor targeting arginase, a critical
immunosuppressive enzyme responsible for T-cell suppression by
myeloid-derived suppressor cells. Arginase depletes arginine,
a nutrient that is critical for the activation, growth and survival
of the body’s cancer-fighting immune cells, known as cytotoxic
T-cells. Calithera is headquartered in South San Francisco,
California. For more information about Calithera, please
visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. The
potential product candidates that Calithera develops may not
progress through clinical development or receive required
regulatory approvals within expected timelines or at all. In
addition, clinical trials may not confirm any safety, potency or
other product characteristics described or assumed in this press
release. Such product candidates may not be beneficial to
patients or successfully commercialized. The failure to meet
expectations with respect to any of the foregoing matters may have
a negative effect on Calithera's stock price. Additional
information concerning these and other risk factors affecting
Calithera's business can be found in Calithera's most recent
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission, and other periodic filings with the Securities
and Exchange Commission at www.sec.gov. These forward-looking
statements are not guarantees of future performance and speak only
as of the date hereof, and, except as required by law, Calithera
disclaims any obligation to update these forward-looking statements
to reflect future events or circumstances.
CONTACT:
Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Sep 2023 to Sep 2024